Enovis CORP reported results for the quarter ended 2026 showing revenue of $582.78M, a 3.2% increase versus the prior-year quarter, and a substantially smaller net loss of ($1.19M) compared with ($36.74M) a year earlier; diluted EPS was ($0.02) versus ($0.64) in the prior-year quarter — per the company’s 10-Q.

Financial Highlights

MetricCurrent quarterPrior year quarterYoY changeRevenue¹$582.78M$564.55M3.2%Net income²($1.19M)($36.74M)96.8%Diluted EPS³($0.02)($0.64)96.9%

¹ Reported as “Net sales”. ² Reported as “Net loss attributable to Enovis Corporation”. ³ Reported as “Net income (loss) per share - basic and diluted”.

Business Highlights

  • Revenue growth was driven by existing-business volume gains across Recon and P&R, with Recon showing strong volume-led growth and margin expansion.
  • Enovis completed the Dr. Comfort U.S. divestiture in October 2025, which reduced P&R sales and refocused the channel and distributor mix.
  • Gross margin expanded due to favorable mix, lower inventory step-up amortization and supply-chain productivity improvements.
  • Integration costs related to the Lima acquisition are moderating while R&D investment increased in Recon for surgical productivity technologies.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.